<p>Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from US regulators as an additional treatment for high risk patients.</p>.<p>Shares of Moderna rise 2.5 per cent to $164 after the market.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/who-calls-for-strengthening-health-systems-for-prevention-early-detection-of-cancer-1187788.html" target="_blank">WHO calls for strengthening health systems for prevention, early detection of cancer</a></strong></p>.<p>The breakthrough tag is granted by the US Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44 per cent compared with Keytruda alone.</p>.<p>The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.</p>.<p>The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023.</p>
<p>Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from US regulators as an additional treatment for high risk patients.</p>.<p>Shares of Moderna rise 2.5 per cent to $164 after the market.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/who-calls-for-strengthening-health-systems-for-prevention-early-detection-of-cancer-1187788.html" target="_blank">WHO calls for strengthening health systems for prevention, early detection of cancer</a></strong></p>.<p>The breakthrough tag is granted by the US Food and Drug Administration (FDA) based on data from a mid-stage study of the drug that showed the therapy reduced risk of skin cancer's recurrence or death by 44 per cent compared with Keytruda alone.</p>.<p>The FDA's breakthrough therapy designation is granted to expedite the development and review of drugs that are intended to treat a serious condition.</p>.<p>The companies said they plans to initiate a late-stage study in adjuvant treatment of melanoma in 2023.</p>